Cortisol Excess
7
3
5
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
EndoSense: Continuous Real-Time Monitoring of Health Markers in Endocrine and Metabolic Disorders
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome
Effects of "Vitamin N" Nature Immersion Therapy on Stress Levels in Health Care Workers in the City of Bogotá
Cerebrovascular Disease: Quality of Life (CODE: QoL)
PATHophysiology of OSteoporosis: Role of Hidden Cortisol Excess and Its Predictors in Bone Fragility
Prevalence of Hidden Hypercortisolism in Osteoporosis